Source and scope
This summary is bounded to the recommendations, population and decisions covered by Guideline No. 454: Identification and Treatment of Perinatal Mood and Anxiety Disorders. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:SOGC 454
Source-attributed clinical priorities
- Screen and assess depression, anxiety, bipolar disorder, psychosis, substance use, trauma, suicide risk and infant safety during pregnancy and postpartum.
- Balance untreated-illness risk with medication and therapy evidence through shared decisions rather than stopping effective treatment abruptly.
- Treat postpartum psychosis, mania or imminent safety risk as an emergency and coordinate obstetric, psychiatric and infant care.
- Screen for bipolar history before treating perinatal depression because postpartum mania risk changes the plan.
sources for this section:SOGC 454
Practical assessment and management workflow
1
Assess mood, anxiety, sleep beyond infant care, intrusive thoughts, psychosis, trauma, substances and supports.
2
Clarify suicide, infant-harm thoughts, intent, insight and ability to provide safe care.
3
Balance illness relapse against fetal, neonatal and breastfeeding medicine considerations with shared decisions.
4
Arrange proactive pregnancy and postpartum follow-up involving obstetric, primary and mental-health teams.
sources for this section:SOGC 454
Safety, red flags and urgent escalation
- Postpartum psychosis, mania, severe depression or intent to harm self or infant is an emergency.
- Do not stop a stable psychotropic abruptly solely because of pregnancy.
- Distinguish unwanted ego-dystonic intrusive thoughts from psychotic beliefs while taking all safety concerns seriously.
sources for this section:SOGC 454
Confirm the local pathway before acting
The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:SOGC 454
Source and implementation boundary
Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:SOGC 454
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- Society of Obstetricians and Gynaecologists of CanadaGuideline No. 454: Identification and Treatment of Perinatal Mood and Anxiety Disordersaccessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page’s provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what—if anything—you may change. Suggestions are never inserted automatically.Browse the Canada question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.